Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, RBC Capital adjusted the price target on Beam Therapeutics Inc. (NASDAQ:BEAM) to $26 from $22 and maintained a Sector Perform rating on the shares. The rating update came after the company reported its fiscal Q4 financial results, with the firm telling investors that Beam Therapeutics Inc. (NASDAQ:BEAM) is continually targeting BLA submission this year on sickle cell disease, and anno ...

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Appl ...

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program on an investor webcast on Tuesday, February 24, 2026, at 8:00 a.m. ET.The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be ...

Industry Overview - Genomics is the comprehensive study of genomes, which has intensified interest among pharmaceutical and biotechnology companies for deeper insights into disease biology and effective therapeutic strategies [1] - The global genomics market was valued at $34.23 billion in 2025 and is projected to grow from $38.24 billion in 2026 to $99.26 billion by 2034, reflecting a compound annual growth rate (CAGR) of 12.66% [8] - The global synthetic biology market was valued at $18.94 billion in 2025 and is expected to reach $69.18 billion by 2033, with a CAGR of 17.7% from 2026 to 2033 [8] Genomic Research and Applications - Insights from genomic research are increasingly used to evaluate patient responses to specific drugs, driving the development of targeted treatments and advancing personalized medicine [3] - The emergence of genome-editing technologies, particularly CRISPR/Cas9 systems, is enabling precise modifications to DNA, offering potential cures for diseases caused by genetic mutations [7] Key Companies - Illumina (ILMN) is a prominent player in genomic sequencing, recognized for its leadership in sequencing and array-based technologies [5] - Pacific Biosciences of California (PACB) focuses on advanced sequencing solutions and has seen its shares rise by 9.1% in the past year, currently holding a Zacks Rank 1 (Strong Buy) [10][12] - Caribou Biosciences (CRBU) is a clinical-stage CRISPR genome-editing biopharmaceutical company, with shares surging 34.4% in the past year and a Zacks Rank 2 (Buy) [12][14] - Sana Biotechnology (SANA) is developing cell engineering platforms for diseases like type 1 diabetes and has seen its shares increase by 37.5% over the past year, also holding a Zacks Rank 2 [15][17]

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 hot stocks to buy with the highest upside potential. On February 9, Sami Corwin from William Blair maintained a Buy rating on Beam Therapeutics. This maintained rating reinforced the bullish outlook that the analyst previously gave on Beam Therapeutics Inc. (NASDAQ:BEAM) in a January 21 note. Corwin noted that the existing clinical data on the lead program of Beam Therapeutics Inc. (NASDAQ:BEAM), the BEAM-302 treatment for alpha-1 antitrypsin deficiency, ...

Group 1 - Beam Therapeutics (NASDAQ:BEAM) is identified as one of the 17 biotechnology stocks with more than 50% upside potential, with a Buy rating and a price target of $80, indicating an upside of over 197% [1] - The company's recent agreement with the U.S. FDA to expedite the approval process for BEAM-302 in alpha-1 antitrypsin deficiency is a significant factor in the positive rating, allowing the use of AAT biomarker data over a 12-month horizon for future BLA [2] - Beam Therapeutics has a strong financial position, with nearly $1.25 billion in cash and marketable securities as of the end of 2025, sufficient to support operations until 2029 and fund the development of BEAM-302 and the anticipated launch of risto-cel [3] Group 2 - UBS analyst Michael Yee assigned a Neutral rating with a $28 price target on January 8, suggesting that more certainty for investors could benefit the biotech sector in 2026, with expectations of major catalysts and attractive pipelines driving returns [4] - Beam Therapeutics focuses on developing precision genetic medicines, engaging in gene therapies and genome editing research, and is a leader in CRISPR-based editing for advanced genetic medicine development [5]

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating and $80 price target for Beam Therapeutics Inc. (NASDAQ:BEAM) on January 15, citing the company’s developments over its BEAM-302 therapy. This comes after Beam announced that it reached an agreement with the FDA on an expedited approval process for BEAM-302 in alpha-1 antitrypsin deficiency (AATD). Pixabay/Public Domain Beam Therapeutics Inc. (NASD ...

Core Insights - Beam Therapeutics Inc. (NASDAQ:BEAM) is recognized as a growth stock and is included in Cathie Wood's Growth Stock Portfolio [1] - Bernstein has maintained an Outperform rating for Beam Therapeutics and raised its price target from $37 to $41, citing a favorable regulatory update for the company's Alpha-1 Antitrypsin Deficiency program as a key catalyst for 2026 [2] - UBS initiated coverage on Beam Therapeutics with a neutral rating and a price target of $28, indicating a broader positive trend in biotechnology fundamentals and investor confidence for 2026 [3] Company Overview - Beam Therapeutics is a biotechnology firm focused on developing a new class of precision genetic drugs [4] - The company is positioned within a sector that is beginning to recover, with expectations for improved performance in 2026 [3] Market Sentiment - Bernstein's positive outlook is driven by upcoming benchmarks, including the release of revised AATD data in Q1 2026, which are critical for investor attention [2] - UBS's coverage initiation reflects a broader trend of improving fundamentals in the biotechnology sector, suggesting a potential rebound in investor confidence [3]

Tempus AI Trade - Ark Invest acquired a total of 13,532 shares of Tempus AI through the ARK Genomic Revolution ETF and ARK Innovation ETF, following a revenue surge of 83% year-over-year for 2025, driven by a 111% increase in diagnostics revenue [2] - The shares closed at $68.36, resulting in an investment of approximately $925,047, with an additional purchase of $5.85 million worth of shares made the previous day [3] WeRide Trade - Ark Invest purchased 166,029 shares of WeRide through the ARK Autonomous Technology & Robotics ETF, as WeRide expanded its global fleet to over 1,000 robotaxis [4] - The shares were acquired at a closing price of $9.05, totaling an investment of approximately $1.5 million [4] Roku Trade - Ark Invest sold 14,885 shares of Roku through the ARK Next Generation Internet ETF at a closing price of $107.23, amounting to approximately $1.6 million [5] - This sale occurred amid mixed analyst forecasts, with Jefferies upgrading Roku to Buy and raising its price target from $100 to $135, indicating an improved outlook for the company [5] Other Key Trades - Ark Invest sold 161,683 shares of Beam Therapeutics Inc. across ARKG and ARKK, 32,227 shares of Unity Software Inc. through ARKW, and 29,533 shares of GitLab Inc. through ARKW [7] - Additionally, the company bought 7,175 shares of Kodiak AI Inc. through ARKQ [7]

Group 1: Netflix Trade - Ark Invest's ARK Next Generation Internet ETF acquired 83,368 shares of Netflix Inc, valued at approximately $7.11 million, following a mixed earnings report where Netflix reported earnings-per-share of 56 cents but provided disappointing first-quarter guidance [2] - Netflix's stock closed at $85.36, down 2.18% from the previous day [2] Group 2: Tempus AI Trade - Ark's ARK Genomic Revolution ETF and ARK Innovation ETF collectively purchased 89,501 shares of Tempus AI, valued at approximately $5.85 million, after the company reported impressive revenue growth of $955 million, a 111% increase year-over-year [3][4] - Tempus AI's stock closed at $65.32, a decrease of 2.19% on Wednesday [4] Group 3: Pinterest Trade - Ark's ARKW fund sold 118,823 shares of Pinterest, valued at approximately $2.97 million, as the company projected fourth-quarter revenue of $1.31–$1.34 billion, slightly below estimates [5] - Pinterest's stock closed at $24.99, down 1.58% [5] Group 4: Other Key Trades - Ark sold 21,286 shares of Beam Therapeutics Inc. and 113,907 shares of GitLab Inc., while purchasing 111,439 shares of WeRide Inc. and 8,817 shares of Trimble Inc [7]